This study aims to determine whether citalopram is a useful, well-tolerated, and safe
treatment for children and adolescents ages 7 to 18 years with functional abdominal pain. The
study hypothesis is that citalopram will be better than placebo in producing clinical
improvement and reductions in abdominal pain. It is also hypothesized that citalopram and
placebo will not differ in terms of safety and tolerability.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
John V. Campo, M.D. National Institute of Mental Health (NIMH)